The US FDA has scheduled a joint meeting of the Bone, Reproductive, and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee for Thursday, June 4, 2015. The committees will discuss the safety and efficacy of flibanserin (100 mg tablets) by Sprout Pharmaceuticals Inc. (Sprout) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.

See the FDA Announcement